AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Organogenesis Inc. (ORGO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.39

-0.14 (-3.97%)

At close: Feb 20, 2025, 3:59 PM

3.38

-0.29%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.37
Market Cap	426.21M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.05
PE Ratio (ttm)	-67.8
Forward PE	n/a
Analyst	Buy

Ask	3.69
Volume	238,860
Avg. Volume (20D)	665,540
Open	3.51
Previous Close	3.53
Day's Range	3.38 - 3.55
52-Week Range	2.17 - 4.57
Beta	undefined

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy ...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 5, 2017

Employees 862

Stock Exchange NASDAQ

Ticker Symbol ORGO

Website https://organogenesis.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for ORGO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 47.49% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Organogenesis Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+28.41%

Organogenesis shares are trading higher after the ... Unlock content with Pro Subscription

9 months ago

+32.89%

Organogenesis shares are trading higher following better-than-expected Q1 earnings.

News

3 months ago · seekingalpha.com

Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript

Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francis...